CN101537172A - 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 - Google Patents
一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 Download PDFInfo
- Publication number
- CN101537172A CN101537172A CN200810030154A CN200810030154A CN101537172A CN 101537172 A CN101537172 A CN 101537172A CN 200810030154 A CN200810030154 A CN 200810030154A CN 200810030154 A CN200810030154 A CN 200810030154A CN 101537172 A CN101537172 A CN 101537172A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- recombinant human
- eye drop
- cell growth
- osmotic pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 35
- 229940012356 eye drops Drugs 0.000 title abstract description 5
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 title abstract 3
- 230000003204 osmotic effect Effects 0.000 claims abstract description 11
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000007853 buffer solution Substances 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- 230000010261 cell growth Effects 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- -1 chelating agen Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 210000003560 epithelium corneal Anatomy 0.000 abstract description 14
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 239000002738 chelating agent Substances 0.000 abstract 1
- 210000004087 cornea Anatomy 0.000 description 19
- 230000035876 healing Effects 0.000 description 13
- 239000003513 alkali Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 206010023683 lagophthalmos Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940116978 human epidermal growth factor Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000002555 descemet membrane Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810030154XA CN101537172B (zh) | 2008-08-14 | 2008-08-14 | 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810030154XA CN101537172B (zh) | 2008-08-14 | 2008-08-14 | 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101537172A true CN101537172A (zh) | 2009-09-23 |
CN101537172B CN101537172B (zh) | 2010-06-30 |
Family
ID=41120714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810030154XA Active CN101537172B (zh) | 2008-08-14 | 2008-08-14 | 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101537172B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656622A (zh) * | 2013-12-04 | 2014-03-26 | 广东暨大基因药物工程研究中心有限公司 | 重组人角质细胞因子kgf-2环境敏感型眼部传递系统及其应用 |
CN110339345A (zh) * | 2019-07-30 | 2019-10-18 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
CN113134078A (zh) * | 2020-01-16 | 2021-07-20 | 温州医科大学 | 含有kgf-2的温敏凝胶剂及其对骨关节炎的治疗作用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−2製剤 |
CN101138629A (zh) * | 2006-09-06 | 2008-03-12 | 上海新生源生物医药有限公司 | 一种重组人角质细胞生长因子-2冻干粉针剂 |
-
2008
- 2008-08-14 CN CN200810030154XA patent/CN101537172B/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656622A (zh) * | 2013-12-04 | 2014-03-26 | 广东暨大基因药物工程研究中心有限公司 | 重组人角质细胞因子kgf-2环境敏感型眼部传递系统及其应用 |
CN103656622B (zh) * | 2013-12-04 | 2015-09-02 | 广东暨大基因药物工程研究中心有限公司 | 重组人角质细胞因子kgf-2环境敏感型眼部传递系统及其应用 |
CN110339345A (zh) * | 2019-07-30 | 2019-10-18 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
CN110339345B (zh) * | 2019-07-30 | 2022-11-29 | 重庆派金生物科技有限公司 | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 |
CN113134078A (zh) * | 2020-01-16 | 2021-07-20 | 温州医科大学 | 含有kgf-2的温敏凝胶剂及其对骨关节炎的治疗作用 |
CN113134078B (zh) * | 2020-01-16 | 2022-08-30 | 温州医科大学 | 含有kgf-2的温敏凝胶剂及其对骨关节炎的治疗作用 |
Also Published As
Publication number | Publication date |
---|---|
CN101537172B (zh) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kitazawa et al. | Trabeculectomy with mitomycin: a comparative study with fluorouracil | |
HO et al. | Kinetics of corneal epithelial regeneration and epidermal growth factor | |
CN102690344B (zh) | 色素上皮衍生因子衍生的多肽对于促进干细胞增殖与伤口愈合的用途 | |
CN103212075A (zh) | 一种含有vegf拮抗剂的滴眼液 | |
JP2020511166A (ja) | 融合タンパク質とその製造方法及び使用 | |
CN111617066B (zh) | Chalcomoracin在制备治疗增生性玻璃体视网膜病变药物中的应用 | |
CN102389392B (zh) | 重组牛碱性成纤维细胞生长因子眼用凝胶 | |
CN101537172B (zh) | 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法 | |
Leibowitz et al. | Effect of topically administered epidermal growth factor on corneal wound strength | |
CN101972224B (zh) | 一种眼用原位凝胶 | |
CN108350458A (zh) | 用豹蛙酶和/或两栖酶治疗病毒性结膜炎 | |
CN109593117B (zh) | 一种用于抑制血管新生的多肽cka18n及其应用 | |
JP2020512015A (ja) | 融合タンパク質とその製造方法及びその眼疾患の治療、抗炎症、抗腫瘍薬物の製造における使用 | |
CN105188731B (zh) | 用于治疗眼部疾病的蛋白质slurp-1 | |
CN103656622B (zh) | 重组人角质细胞因子kgf-2环境敏感型眼部传递系统及其应用 | |
CN102336812B (zh) | 一种具有抑制血管生成活性的多肽 | |
CN110339345B (zh) | 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用 | |
JP2023035974A (ja) | ナノ低分子ペプチドfg及びその眼底血管疾患の治療や予防用薬物の調製への応用 | |
CN102008488A (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
KR20230007963A (ko) | 이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물 | |
CN110604811B (zh) | 含有重组人溶菌酶和重组人表皮生长因子的人工泪液 | |
CN110604812B (zh) | 一种含有重组人溶菌酶的人工泪液 | |
CN108721315A (zh) | 小分子核酸miR-21在治疗青光眼中的应用 | |
US20230022990A1 (en) | Compositions of growth factor for the treatment of eye disease | |
US20220168434A1 (en) | Application of transthyretin in entering eye and preparing drop |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Wang Xiaojie Document name: Notification that Application Deemed not to be Proposed |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Wang Xiaojie Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No.82, Xueyuan West, Wenzhou, Zhejiang 325027 Patentee after: WENZHOU MEDICAL University Patentee after: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. Patentee after: JILIN AGRICULTURAL UNIVERSITY BIOREACTOR ENGINEERING Co.,Ltd. Address before: 325035 School of pharmacy, Wenzhou Medical College, Wenzhou, Zhejiang Patentee before: WENZHOU MEDICAL College Patentee before: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. Patentee before: JILIN AGRICULTURAL UNIVERSITY BIOREACTOR ENGINEERING Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210428 Address after: Building a, life and health town innovation center, Sanlong street, Ouhai District, Wenzhou City, Zhejiang Province Patentee after: Wenzhou Deyu Pharmaceutical Technology Co.,Ltd. Patentee after: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. Address before: No.82, Xueyuan West, Wenzhou, Zhejiang 325027 Patentee before: WENZHOU MEDICAL University Patentee before: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. Patentee before: JILIN AGRICULTURAL UNIVERSITY BIOREACTOR ENGINEERING Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210517 Address after: 510000 5th floor, building B5, 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU LIXIN PHARMACEUTICALS Co.,Ltd. Address before: Building a, life and health town innovation center, Sanlong street, Ouhai District, Wenzhou City, Zhejiang Province Patentee before: Wenzhou Deyu Pharmaceutical Technology Co.,Ltd. Patentee before: GUANGDONG JIDA GENETIC MEDICINE ENGINEERING RESEARCH CENTER Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211214 Address after: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee after: Guangzhou Lixin Biotechnology Co.,Ltd. Address before: 510000 5th floor, building B5, 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD. |